Cargando…

Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma

BACKGROUND: Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors of the head and neck. Programmed cell death protein 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) are often overexpressed in OSCC patients, and their expression level is closely related to tumor progn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Liang, Yin, Ke, Zhang, Suxin, Chen, Zhong, Bao, Yang, Li, Tianke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482888/ https://www.ncbi.nlm.nih.gov/pubmed/36133741 http://dx.doi.org/10.2147/CMAR.S368738

Ejemplares similares

Variation and significance of secretory immunoglobulin A, interleukin 6 and dendritic cells in oral cancer
por: Zhang, Suxin, et al.
Publicado: (2017)

Using weighted gene co-expression network analysis to identify key modules and hub genes in tongue squamous cell carcinoma
por: Yin, Ke, et al.
Publicado: (2019)

The exploration of new biomarkers for oral cancer through the ceRNA network and immune microenvironment analysis
por: Ma, Sai, et al.
Publicado: (2022)

Tumor microenvironment characterization in head and neck cancer identifies prognostic and immunotherapeutically relevant gene signatures
por: Huo, Mengqi, et al.
Publicado: (2020)

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
por: Liu, Sixue, et al.
Publicado: (2021)

Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma
por: Scuderi, Sarah Adriana, et al.
Publicado: (2021)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

Stathmin guides personalized therapy in oral squamous cell carcinoma
por: Ju, Wu‐tong, et al.
Publicado: (2020)

Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
por: Knochelmann, Hannah M., et al.
Publicado: (2021)

A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy
por: Ji, Shoujian, et al.
Publicado: (2023)

Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study
por: Dave, Kanan, et al.
Publicado: (2020)

Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity
por: Saeed, Saleha, et al.
Publicado: (2022)

Corneodesmosin as a potential target of oral squamous cell carcinoma
por: Di, Yong-Bin, et al.
Publicado: (2022)

ESRRG-PKM2 axis reprograms metabolism to suppress esophageal squamous carcinoma progression and enhance anti-PD-1 therapy efficacy
por: Wang, Tianxiao, et al.
Publicado: (2023)

p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses
por: Miao, Lei, et al.
Publicado: (2020)

Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
por: Blatt, Sebastian, et al.
Publicado: (2022)

Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma
por: Steen, Sonja, et al.
Publicado: (2023)

Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo
por: Liang, Si-yuan, et al.
Publicado: (2021)

Low Survival Rates of Oral and Oropharyngeal Squamous Cell Carcinoma
por: Le Campion, Anna Carolina Omena Vasconcellos, et al.
Publicado: (2017)

Survival and prognostic factors in patients with oral squamous cell carcinoma
por: Ferreira, Andressa Kelly Alves, et al.
Publicado: (2021)

Metronomic Therapy in Oral Squamous Cell Carcinoma
por: Su, Nai-Wen, et al.
Publicado: (2021)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
por: Ju, Wu-tong, et al.
Publicado: (2022)

HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
por: Wang, Jian, et al.
Publicado: (2019)

Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
por: Furkert, Chris, et al.
Publicado: (2023)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

Epithelial PD‐L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan
por: Gaafar, Nuha M., et al.
Publicado: (2022)

Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma
por: Ahn, Hyein, et al.
Publicado: (2017)

Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma
por: Fu, Ze-Ming, et al.
Publicado: (2022)

Prognostic value of inflammation‐immunity‐nutrition score in patients with hepatocellular carcinoma treated with anti‐PD‐1 therapy
por: Zhang, Zilong, et al.
Publicado: (2022)

PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
por: Tojyo, Itaru, et al.
Publicado: (2019)

Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
por: Kitichotkul, Kit, et al.
Publicado: (2022)

High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
por: Lin, Yueh-Min, et al.
Publicado: (2015)

Increasing incidence and improving survival of oral tongue squamous cell carcinoma
por: Kim, Yi-Jun, et al.
Publicado: (2020)

Impact of oral anti–hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization
por: Zhou, Zhong-Guo, et al.
Publicado: (2015)

High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments
por: Adamski, Łukasz Jan, et al.
Publicado: (2021)

The relation between NEAT1 expression level and survival rate in patients with oral squamous cell carcinoma
por: Lin, Nan-Chin, et al.
Publicado: (2022)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
por: Alloghbi, Abdurahman, et al.
Publicado: (2021)

PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2022)

A Novel Immune-Associated Gene Signature for Overall Survival Prediction in Patients with Oral Squamous Cell Carcinoma
por: Yang, Jian, et al.
Publicado: (2022)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dgoalgfta4eo1oet4nbjqg17h2